logo
  

Toyota Lifts Production Forecast For FY23

Japanese automaker Toyota Motor Corp. (TYT.L,TM) Monday said it is currently projects a baseline production volume with a ceiling of 10.6 million units for 2023, with a downward risk fluctuation range of around 10%.

However, as in the previous year, the impact of parts supply shortages such as semiconductors remains unclear.

Toyota's previous production forecast for the fiscal year was at approximately 9.2 million.

According to the company, the repeated adjustments to production plan was due to the spread of COVID-19 and shortages of parts such as semiconductors.

The company said, "The situation this year remains difficult to predict due to factors such as semiconductor shortages and the spread of COVID-19. However, we will continue to carefully examine parts supplies and supplier situations to create more stable production plans and reduce supplier burdens, while considering all possible production fluctuation measures to ensure that we can deliver as many vehicles as possible to our customers at the earliest date."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
Follow RTT